Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oral Cannabinoid Formulations vs Sativex
NCT03201835Phase 1Completed
- Sponsor
- PhytoTech Therapeutics
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dronabinol and Zygel in multiple sclerosis (MS) and epilepsy (5 arms), sponsored by PhytoTech Therapeutics. Primary endpoint: Frequency, severity, and duration of adverse events at 8 weeks. Started Sep 2015; status: completed.
02
Drugs
dronabinolZygel
03
Conditions
multiple sclerosis (MS)epilepsy
Beyond the preview
Go deeper on NCT03201835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201835.